Method of treating an IL-1 related cancer
View Patent ↗Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1β binding antibody or IL-1β binding fragment thereof. An IL-1β binding antibody or IL-1β binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.
1. A method of treating a cancer in a mammal comprising administering an effective amount of an IL-1 binding antibody or IL-1 binding fragment thereof, said antibody or fragment comprising a heavy chain variable region of SEQ ID NO: 15 and a light chain variable region of SEQ ID NO: 11, wherein the cancer is multiple myeloma, acute myelogenous leukemia or chronic myelogenous leukemia.
2. The method of claim 1 , wherein the cancer is multiple myeloma.
3. The method of claim 1 , wherein the cancer is acute myelogenous leukemia.
4. The method of claim 1 , wherein the cancer is chronic myelogenous leukemia.
5. The method of claim 1 , wherein the mammal is a human.
6. The method of claim 1 , wherein the effective amount of the antibody or antibody fragment is effective to inhibit IL-1 induced expression of serum IL-6 in an animal by at least 50% as compared to the level of serum IL-6 in the absence of the antibody.
7. A method of treating a cancer in a mammal comprising administering an effective amount of an IL-1 binding antibody or IL-1 binding fragment thereof, wherein the antibody or fragment binds to human IL-1 with a dissociation constant less than 1 pM, and the antibody or fragment competes with the binding of an antibody comprising the light chain variable region of SEQ ID NO: 11 and the heavy chain variable region of SEQ ID NO: 15, wherein the cancer is multiple myeloma, acute myelogenous leukemia or chronic myelogenous leukemia.
8. The method of claim 7 , wherein the cancer is multiple myeloma.
9. The method of claim 7 , wherein the cancer is acute myelogenous leukemia.
10. The method of claim 7 , wherein the cancer is chronic myelogenous leukemia.
11. The method of claim 7 , wherein the mammal is a human.
12. The method of claim 7 , wherein the effective amount of the antibody or antibody fragment is effective to inhibit IL-1 induced expression of serum IL-6 in an animal by at least 50% as compared to the level of serum IL-6 in the absence of the antibody.